On December 8, 2015 CELLIPSE reported that during the 57th American Society of Hematology (ASH) (Free ASH Whitepaper) Congress held in Orlando, the teams from U. of Indiana Wells Center led by Pr Kapur and Institut Albert Bonniot led by Dr Lafanechère presented the results of their work in the session dedicated to Oncogene and Tumor Suppressors in Myeloïd malignancies (Press release, CELLIPSE, DEC 8, 2015, View Source [SID:1234508500]). This new data reinforces the rationale for looking into LIM Kinase inhibition to stop downstream oncogene signaling of specific mutations of Tyrosine Kinase Receptors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CELLIPSE is developing selective and highly potent LIM Kinase small molecule inhibitors to bring new targeted therapies against cancer indications with poor overall prognosis and high medical need such as Acute Myeloïd Leukemia and Myeloproloferative Neoplasms.